Program for the Inaugural Australian Respiratory Virology Meeting

University of Canberra

**Friday December 4th:**

**8.15 – 8.30am: Welcome and official opening by Stephen Parker, Vice-Chancellor of University of Canberra**

|  |  |  |
| --- | --- | --- |
| **Session 1:** | **Antiviral Therapies** | **Chair: Reena Ghildyal** |
| **8.30 – 9.10** | **Peter Openshaw** | **Keynote Speaker, University of Canberra, DV-R Distinguished Visitor Scheme** |
| 9.10 – 9.30 | Patrice Guillon | Structure-guided discovery of potent and dual-acting human PIV3 HA-NA inhibitors |
| 9.30 – 9.50 | Daniel Clarke | Improving therapeutic outcomes of RSV treatment via intravenous liposomal delivery of siRNA to the lung |
| 9.50 – 10.10 | Malcolm Starkey | Tristetraprolin/ZFP36 is protective against influenza virus infection in mice |

**10.10 – 10.50am coffee break**

|  |  |  |
| --- | --- | --- |
| **Session 2:** | **Cellular interactions and host response I** | **Chair: Kirsten Spann** |
| **10:50 – 11:30** | **Peter Wark** | **Keynote Speaker, sponsored by Lonza** |
| 11.30 – 11.50 | Keiko Kan-o | The effects of fluticasone propionate on hMPV infection of human primary epithelial cells and fibroblasts |
| 11:50 – 12:10 | Benjamin Bailly | Cyclopamine targets human RSV transcription anti-termination factor M2-1 and inhibits viral replication *in vivo* |
| 12:10 – 12.30 | Kirsten Spann | Asthma is associated with impaired apoptosis of epithelial cells infected with hMPV |

**12.30 – 1:30pm lunch and trade display by LONZA**

|  |  |  |
| --- | --- | --- |
| **Session 3:** | **Cellular interactions and host response II** | **Chair: Patrick Reading** |
| **1:30 – 2.10** | **Ralph Tripp:** | **Keynote Speaker, sponsored by the Australasian Society for Immunology** |
| 2.10 – 2.30 | Sarah Londrigan | Friend or foe: how do macrophages control (or facilitate) influenza A virus disease severity? |
| 2.30 – 2.50 | David Jans | Host targets of RSV matrix protein |
| 2.50 – 3.10 | Patrick Reading | Attachment factors, entry receptors and pathways for internalization of respiratory viruses |

**3.10 – 3.50pm coffee break**

|  |  |  |
| --- | --- | --- |
| **Session 4:** | **Viral immunology** | **Chair: Kirsten Spann** |
| **3:50 – 4.30** | **Katherine Kedzierska** | **Keynote Speaker** |
| 4:30– 4.50 | Angela Pizzolla | Nasal resident memory CD8+ T cells are highly protective against influenza A infection |
| 4.50 – 5:10 | Malcolm Starkey | IL-13 predisposes to more severe influenza infection in mice and human epithelial cells by suppressing interferon responses and activating the miRNA-21/PI3K signalling pathway |
| 5:10 – 5.30 | Belinda Thomas | Influenza A infection is exacerbated in a mouse model of lung-specific TGFβ over-expression |

**6pm: Dinner at Zierholz, University of Canberra**

**Saturday December 5th:**

|  |  |  |
| --- | --- | --- |
| **Session 5:** | **Keynote speaker & student talks** | **Chair: Reena Ghildyal** |
| **8.30 – 9.10** | **Peter Openshaw** | **Keynote speaker** |
| 9:10 – 9.25 | Fernanda Ana Sosa | Influenza-specific antibody-dependent phagocytosis |
| 9.25-9.40 | Lien Anh Ha Do | RSV and other viruses in Vietnamese hospitalised children under two years old |
| 9.40-9.55 | Sarah Croft | Human rhinovirus 3C protease cleaves RIPK1, an important intermediate in extrinsic apoptosis |

**9.55 – 10.15am coffee break**

|  |  |  |
| --- | --- | --- |
| **Session 6:** | **Student talks** | **Chair: Patrick Reading** |
| 10.15 – 10.30 | Robert Allen | Exploring the impact of influenza neuraminidase activity and substrate specificity in host infection |
| 10.30 – 10.45 | Larissa Dirr | The catalytic mechanism of PIV3 HA-NA revealed |
| 10.45 – 11.00 | Hillary Vanderven | TBA (influenza and ADCC) |
| 11.15 – 11.30 | Tanguy Eveno | Exploring human PIV-1 HA-NA as a target for inhibitor discovery |

**11:30 – 11:45: Judges deliberation and announcement of student award**

**11:45: Closing Remarks and Thanks by DVC-R UC Prof Frances Shannon**